The pharmacology of nicotinic receptor-mediated seizures was investigated in C3H mice. Eleven nicotinic agonists and six antagonists were administered centrally (i.c.v.). Epibatidine and epiboxidine were the most potent agonists tested, whereas acetylcholine and the ␣7*-selective compounds 3-(2,4-dimethoxybenzylidene)-anabaseine (GTS-21) and anabasine, were the least potent. Nicotine-induced seizures were blocked by cotreatment with either the nonselective antagonist mecamylamine or the ␣7*-selective antagonist methyllycaconitine. The ␣4␤2*-selective antagonist dihydro-␤-erythroidine was ineffective at blocking seizures. However, high doses of all six antagonists tested were fully efficacious in producing seizures, with d-tubocurarine being the most potent and mecamylamine the least potent. Potential relationships between nicotinic receptor-mediated seizures and drug effects on GABA function were also investigated. No correlation was seen between potencies of the agonists in producing seizures and We also compared inbred mouse strain sensitivity to nicotine, picrotoxin, bicuculline, and kainate-induced seizures. Robust positive correlations were revealed for nicotine-induced seizures and seizures induced by either picrotoxin or bicuculline, both GABA A receptor antagonists. No correlation was found between nicotineinduced seizures and those induced by the excitatory amino acid receptor agonist kainate. Based on these findings, we present a model for nicotinic receptor-mediated seizures mediated through GABAergic systems.
Nicotine produces a variety of behavioral effects, some stimulant and others depressant. For example, high doses of nicotine cause seizures (Miner and Collins, 1989; Damaj et al., 1999) , whereas lower doses of nicotine decrease or reduce anxiety (for review, see Picciotto et al., 2002) . It is highly likely that most, if not all, of the effects of nicotine are mediated by nicotinic cholinergic receptors (nAChRs) because nAChR antagonists block many of nicotine's effects. Mammalian brain expresses nine distinct nAChR subunit genes, designated ␣2 to ␣7 and ␤2 to ␤4, which are expressed in a regionally specific manner in the brain and spinal cord (for review, see Itier and Bertrand, 2001 ). This finding suggests that many different nAChR subtypes might exist, assuming that nAChRs expressed in the brain and spinal cord are, like the muscle-type nAChRs, composed of five subunits.
In recent years, many studies have been geared toward identifying the subunit compositions of the naturally occurring nAChRs. The two most abundant nAChRs are the ␣4␤2* and ␣7* types, which bind nicotine and ␣-bungarotoxin with high affinity, respectively (Buisson and Bertrand, 2002) . Note that the * indicates the possibility that other subunits may be included in the native receptor as recommended by the International Union of Pharmacology nomenclature committee. The finding that multiple subtypes of nAChRs probably exist raises the question, Are specific nAChR subtypes involved in mediating each of the various effects of nicotine?
We have been especially interested in identifying which nAChRs modulate brain excitability, as measured by nicotine-induced seizures. In vivo electrophysiological recordings revealed that high doses of nicotine elicit seizures that originate in the hippocampus (Cohen et al., 1981) . However, the possibility exists that nicotinic compounds elicit seizures in areas other than the hippocampus such as the thalamocortical pathways that may be involved in autosomal dominant nocturnal frontal lobe epilepsy, which is associated with poly-morphisms in the ␣4 and ␤2 nAChR subunits (for review, see Raggenbass and Bertrand, 2002) . Two strategies, genetic and pharmacological, have been used to identify the nAChR subtypes that mediate this response to nicotine. Early genetic data indicated the involvement of ␣7* receptors based on the finding that seizure sensitivity is significantly correlated with levels of ␣-bungarotoxin binding in the hippocampus of multiple inbred mouse strains (Miner and Collins, 1989) . Subsequent studies found that this correlation persisted in F2 hybrids derived from two of the inbred strains (DBA/2 and C3H) that differ maximally in sensitivity to nicotine-induced seizures (Stitzel et al., 1998) . However, studies done with mice with genetically modified ␣7 receptors have yielded confounding results: ␣7-null mutant mice show no difference in susceptibility to nicotine seizures (Franceschini et al., 2002) , whereas mice engineered to express an ␣7 "gain of function" receptor exhibit an increased sensitivity to nicotine-induced seizures .
A recent report presented pharmacological data suggesting that nicotine-induced seizures result from increased glutamatergic synaptic transmission due to ␣7* receptor stimulation (Damaj et al., 1999) . This interpretation may be correct, but it neglects the fact that ␣7* receptors are located on GABAergic interneuron cell bodies and nerve terminals (Frazier et al., 1998a,b; Alkondon and Albuquerque, 2001 ) in addition to the nerve terminals and distal dendrites of glutamatergic neurons (Ji et al., 2001) . Furthermore, more recent genetic studies argue that nicotine can elicit seizures via effects on other nAChR subtypes. For example, we (Stitzel et al., 1998 (Stitzel et al., , 2000 found that polymorphisms associated with the ␣4, ␣5, and ␣6 subunits are associated with variability among mouse strains in nicotine-induced seizure sensitivity, and Fonck et al. (2003) recently reported that mice designed to express ␣4 gain of function nAChRs are exquisitely sensitive to nicotine-induced seizures. These reports suggest that nicotine may elicit seizures by modulating the activities of more than one nAChR subtype.
The following report extends the pharmacological analysis of nAChR-mediated seizures reported previously (Damaj et al., 1999) by determining the ability of additional nicotinic agonists to elicit seizures and by determining the ability of nicotinic antagonists to both block and induce seizures. We also compare the seizure-inducing ability of nicotinic agents to their effects on GABAergic function. Finally, we propose alternate explanations for the mechanism of these seizures.
Materials and Methods
Materials. Methyllycaconitine (MLA) citrate, (ϩ)-anatoxin-␣ hydrochloride, and methylcarbachol chloride were purchased from Sigma/RBI (Natick, MA). ABT-418 was a gift from Abbott Diagnostics (Abbott Park, IL). Mecamylamine was a gift from Merck (Whitehouse Station, NJ). The following compounds were purchased from Sigma-Aldrich (St. Louis, MO): nicotine hydrogen (Ϫ)-tartrate (Lnicotine), d-tubocurarine (dTC), dihydro-␤-erythroidine (DH␤E) HBr, acetylcholine chloride (ACh), cytisine, (Ϯ)-epibatidine-L-tartrate, epiboxidine-chloride, tetramethylammonium (TMA) iodide, (Ϯ)-anabasine, dimethylphenylpiperazinium iodide (DMPP), decamethonium, and hexamethonium. All drug solutions were made fresh in 0.9% sterile saline the day of the experiment.
Animals. Male and female C3H/2 mice were used in the study. The animals were bred at the Institute for Behavioral Genetics and were housed five per cage with free access to food and water. The vivarium was maintained on a 12-h light/12-h dark cycle with lights on between 7:00 AM and 7:00 PM. The animals were 60 to 90 days of age at the time of use. The animal care and experimental procedures used were approved by the University of Colorado's Animal Care Committee and are in accordance with the National Institutes of Health Guide for Care and Use of Laboratory Animals. Intraventricular Injections. A major factor that limits the value of pharmacological analyses of nicotinic actions is that the absorption, distribution, and metabolism of many of the nicotinic drugs that are readily available have not been described in adequate detail. We attempted to circumvent the lack of pharmacokinetic data for these compounds by injecting them directly into the brain. Intraventricular injections were performed according to the method of Pedigo et al. (1975) . Briefly, an incision was made in the scalp such that bregma was exposed. Injections were performed using a 26-gauge needle with a sleeve of polyethylene 20 tubing to control the depth of the injection. Mice were administered each drug, or saline as a control, in an injection volume of 5 l at a site 2 mm caudal and 2 mm lateral to the bregma at a depth of 2 mm. Mice were not administered an anesthetic before i.c.v. injection. None of the mice administered the saline control experienced seizures. Immediately after seizure testing, the dye, Fast Blue, was injected. Data obtained from mice in which the ventricles were stained with Fast Blue were used for analysis.
Seizure Testing. After the injection of nicotinic agents, each animal was placed in a 30-cm-diameter round Plexiglas cage and observed for up to 5 min or conclusion of seizure. Behavioral changes typically occurred within 1 to 3 min, depending on the drug dose. Agonist-induced seizures were scored using the following scoring system: 0, no visible effect; 1, sedation and/or straub (i.e., rigid) tail; 2, mild head and/or body tremors; 3, any of the following, severe tremors, wild running, loss of righting, forelimb clonus; 4, clonic convulsion (all limbs); 5, tonic hind limb extension; and 6, death. Antagonist-induced seizures were scored using the following scale: 0, no visible effect; 1, altered/shortened gait; 2, decreased motion/sedation; 3, teeth clicking; 4, tremors/ataxia; 5, straub tail, forelimb clonus; 6, clonic convulsion (all limbs); and 7, tonic hind limb extension/death. The effects of antagonists on agonist-induced seizures were usually done by simultaneously injecting (i.c.v.) the antagonist and an ED 80 dose of nicotine. In cases where no antagonism was seen, mice were pretreated (3 min, i.c.v. administration) with the antagonist followed by challenge with an ED 80 dose of nicotine (5 mg/kg) given by intraperitoneal injection.
Data Analysis. ED 50 values (the agonist doses that elicited seizures in 50% of the test animals), with standard errors for seizure scores, were determined using the Hill equation. ED 50 values, with 95% confidence limits, for percentage of clonic seizures were determined according to the method of Litchfield and Wilcoxon (1949) . Potential relationships between seizures and measures of GABA function, and between nicotine-induced seizures and those induced by other convulsant agents, were determined using regression analysis.
Results
Agonist Pharmacology of Nicotinic Receptor-Mediated Seizures. The ability of 11 nicotinic receptor agonists to elicit seizures in adult (60 -90-day-old) C3H/2 mice was tested. Figure 1 shows the seizure dose-response curves for these agonists. The data are presented as the percentage of mice experiencing clonic seizures on the right abscissa, and mean seizure scores for each dose are presented on the left abscissa. Drug doses are given on the ordinate. All 11 agonists induced seizures in at least 90% of the mice with the exception of cytisine. (Ϯ)-Epibatidine, and its analog epiboxidine, were the most potent, whereas ACh was the least potent of the agonists exhibiting full efficacy. Because anticho-linesterases were not coadministered with ACh, its potency was likely to be underestimated due to hydrolysis decreasing the amount of ACh that reached the receptors. The ␣7*-selective compound GTS-21 and its parent compound anabasine were also low in potency. ABT-418, a compound with high affinity for ␣4␤2* nAChRs and low affinity for ␣7* nAChRs (Arneric et al., 1994) , was fully efficacious as a seizure-inducing agent, whereas cytisine was only partially effective in eliciting seizures with only 25% of the mice displaying clonic seizures. The pharmacological potency for agonist-induced seizures is listed in Table 1 , along with the fatality rates (percentage of mice that died) at doses that induced clonic and or tonic seizures.
Nicotinic Antagonist Blockade of Nicotine-Induced Seizures. The ability of nicotinic agonists to elicit seizures suggests that activation of nicotinic receptors by high doses of agonists is proconvulsant. To test this assertion, we determined the ability of nicotinic antagonists to block nicotineinduced seizures. Figure 2 shows the results of these experiments. The nonselective nicotinic antagonist mecamylamine produced a dose-dependent blockade of nicotine-induced seizures with a dose of 100 g/mouse blocking 100% of the seizures ( Fig. 2A) . The ␣7*-selective antagonist MLA was ineffective at blocking nicotine-induced seizures when administered (i.c.v.) simultaneously with nicotine (Fig. 2B) .
However, when MLA was administered 3 min before (i.c.v.) to nicotine (5 mg/kg i.p.), it was partially effective at blocking seizures (Fig. 2B, inset) . This difference may indicate that MLA and nicotine differ significantly in their ability to diffuse from the cerebral ventricles to the receptor sites. The ␣4␤2*-selective antagonist DH␤E was ineffective at blocking nicotine-induced seizures (Fig. 2C) . These results confirm those obtained by Damaj et al. (1999) .
Antagonist-Induced Seizures. Previous studies have shown that curare (dTC) and ␣-bungarotoxin, when administered i.c.v., elicit seizures (Cohen et al., 1981; Stevens et al., 1995) . Figure 3 shows the results of those experiments that assessed the potential seizure-inducing effects of six antagonists. All six antagonists that were tested were fully efficacious for inducing seizures. dTC was the most potent for eliciting seizures, whereas mecamylamine was the least potent. Except for dTC and mecamylamine, the ED 50 values for antagonist-induced seizures were very similar (Table 1) . Mice given MLA began to exhibit seizure behavior at a dose (30 g/mouse) just above that which produced partial blockade of nicotine-induced seizures. The ␣4␤2*-selective antagonist DH␤E, although ineffective at blocking nicotine-induced seizures, was fully efficacious in eliciting seizures. A major difference was observed between agonist-and antagonist-induced seizures: death was the usual outcome after Correlation between Nicotinic Receptor-Mediated Effects on [ 3 H]GABA Release and ED 50 for AgonistInduced Seizure. The ability of nicotinic antagonists to elicit seizures indicates that nicotinic receptor activation is not necessary for seizure induction and that decreased nicotinic receptor function is also proconvulsant. Furthermore, this suggests that seizures could also result from agonistinduced desensitization of nicotinic receptors. Indeed, rapid desensitization is a well documented characteristic of several types of nicotinic receptors (including the ␣7* and ␣4␤2* types). Because most of the nicotinic receptors in the hippocampus seem to be expressed on GABAergic interneurons (Frazier et al., 1998a; Alkondon and Albuquerque, 2001) (Lu et al., 1998) . These values were compared with the agonist potencies for seizure induction determined in the present study. Eight of the agonists (nicotine, ACh, methylcarbachol, DMPP, TMA, epibatidine, epiboxidine, and anabasine), and all six antagonists tested in the present study were used in our previous study that evaluated the effects of nicotinic agonists and antagonists on [ 3 H]GABA release from mouse brain synaptosomes (Lu et al., 1998) . No significant correlation was found between the potencies of the agonists in stimulating [
3 H]GABA release and the potencies of the agonists in producing seizures (r ϭ 0.48, p Ͼ 0.05; Fig. 4A ). Comparisons of the potencies of the antagonists in producing seizures and antagonism of nicotineinduced [
3 H]GABA release also failed to exhibit a significant relationship (r ϭ Ϫ0.38, p Ͼ 0.05; Fig. 4B (Lu et al., 1999 ) and potencies of the agonists in producing seizures yielded a strong positive correlation (r ϭ 0.93, p Ͻ 0.01; Fig. 4C ).
Genetic Relationship between Nicotine-Induced Seizures and Seizures Induced by Other Convulsants. Previous studies from our laboratory demonstrated that inbred mouse strains differ in sensitivity to nicotine-induced seizures (Miner and Collins, 1989) . Inbred mouse strains also differ in sensitivity to seizures induced by convulsants acting through several different receptor systems (Kosobud and Crabbe, 1990; Kosobud et al., 1992) . The relationship between nicotine-induced seizures and seizures induced by agents acting on GABAergic, and glutamatergic systems was determined by regression analysis of seizure sensitivity for the inbred mouse strains common to both studies. Data for nicotine-induced seizures were obtained from Miner and Collins (1989) , and data for bicuculline-, picrotoxin-and kainateinduced seizures were obtained from Kosobud and Crabbe (1990) Lu et al. (1998 Lu et al. ( , 1999 . A, no significant relationship (r ϭ 0.48, p Ͼ 0.05) exists between agonist potency for eliciting seizures and agonist potency for eliciting Miner and Collins (1989) . The data for picrotoxin-, bicuculline-, and kainate-induced seizures was obtained from Kosobud and Crabbe (1990) . The correlation coefficient for each relationship is given in the corresponding panel.
Discussion
All of the agonists tested, with the exception of cytisine, were fully efficacious in eliciting seizures. These findings, coupled with the antagonist results (MLA and mecamylamine blocked nicotine-induced seizures, whereas pretreatment with DH␤E did not), extend the findings of Damaj et al. (1999) who concluded that nicotinic agonists induce seizures via an effect on ␣7* nAChRs. The conclusion that ␣7* nAChRs modulate seizures is consistent with the observations that nicotine-induced seizure sensitivity is correlated with levels of hippocampal ␣-bungarotoxin binding in genetically segregating mouse populations (Miner et al., 1984; Miner and Collins, 1989; Stitzel et al., 1998) , and mice engineered to express an ␣7 gain of function mutation (L250T) are supersensitive to nicotine-induced seizures . Damaj et al. (1999) proposed that the activation of ␣7* receptors located on glutamatergic nerve terminals is the major stimulus that results in nicotine-induced seizures. It has been shown that nicotine enhances glutamate release when applied to embryonic chicken medial habenula-interpeduncular nucleus cocultures (McGehee et al., 1995) and CA1 pyramidal neurons obtained from 14-to 24-day-old mice (Ji et al., 2001 ). However, the finding (Aramakis and Metherate, 1998) that ␣7* receptor enhancement of N-methyl-Daspartate receptor-mediated synaptic transmission in rat sensory neocortex is seen only in tissue from p8-p19 postnatal rats suggests that an ␣7-glutamate hypothesis should be accepted with caution. Moreover, our finding that higher doses of MLA induced seizures, coupled with the observation that the ␣7*-selective antagonist ␣-bungarotoxin also elicits seizures (Cohen et al., 1981) , suggests other, or additional mechanisms, may exist. The results obtained with ABT-418 support a role for ␣4␤2-type receptors in modulating seizures. ABT-418 has a K i value of 3 nM for ␣4␤2* nAChRs and a K i value of Ͼ10,000 nM for ␣7* nAChRs (Arneric et al., 1994) . The finding that cytisine, a partial agonist for ␣4␤2* receptors and a full agonist at ␣7* nAChRs (Chavez-Noriega et al., 1997; Houlihan et al., 2001) , was a partial agonist for seizures also argues that seizures may be generated via effects on ␣4␤2* nAChRs. The cytisine findings suggest that a minimum level of ␣4␤2* function may be required for seizures to occur. Alternatively, the rate of ␣4␤2* desensitization is much slower for cytisine than other agonists (Lu et al., 1999) . Thus, the resulting current through ␣4␤2* receptors, although lower in peak amplitude, will be of greater duration and result in a greater total charge movement. This would most likely result in increasing the efficacy of GABAergic synaptic transmission by either increasing the probability of GABA release via increased ␣4␤2* activity (increased depolarization and Ca 2ϩ influx) on GABAergic nerve terminals, or by increasing the probability of action potential generation via increased ␣4␤2* activity (depolarization) on GABAergic somata, or both.
The fact that GTS-21 produced seizures may implicate ␣7* receptors because it is a potent (although partial) agonist at these receptors; however, it also blocks ␣4␤2* receptors at the same concentrations (de Fiebre et al., 1995) . This fact suggests that blocking ␣4␤2* receptors may elicit seizures and is supported by our finding that the ␣4␤2*-selective antagonist DH␤E, although ineffective in blocking nicotineinduced seizures, is fully efficacious in eliciting seizures.
Genetic evidence also argues for a role for ␣4␤2* nAChRs in generating seizures. Stitzel et al. (2000) detected an association between a polymorphism in the mouse ␣4 nAChR gene and sensitivity to nicotine-induced seizures in a panel of recombinant inbred mouse strains, and Fonck et al., (2003) found that mice that express an ␣4 gain of function mutation are supersensitive to nicotinic agonist-induced seizures. The finding that ␣4 null-mutant mice have a lower threshold for pentylenetetrazol-and bicuculline-induced seizures (Wong et al., 2002) , and the finding that a heritable seizure disorder in humans (autosomal dominant nocturnal frontal lobe epilepsy) is associated with polymorphisms in the ␣4 and ␤2 genes (Raggenbass and Bertrand, 2002 ) also suggest that seizures may result from altered activity of ␣4␤2* nAChRs.
␣7* receptors are expressed on the cell bodies and dendrites of many, but not all, GABAergic interneurons in the hippocampus (Frazier et al., 1998a,b) . Stimulation of these interneurons results in somatic and dendritic inhibition of pyramidal cells (Buhler and Dunwiddie, 2002) , as well as inhibition of other interneurons (Alkondon et al., 1998 (Alkondon et al., , 2000 Ji and Dani, 2000) . Nicotine-stimulated [
3 H]GABA release from synaptosomes is mediated by ␣4␤2* receptors as demonstrated by the findings that nicotine-stimulated [
3 H]GABA release is abolished in both ␤2 (Lu et al., 1998) and ␣4 null mutant mice (S. McCallum and A. C. Collins, unpublished observations). These findings support the hypothesis that altering the nicotinic modulation of GABAergic neurons can elicit seizures.
Three potential mechanisms for nicotine-induced seizures, two of these involving the GABAergic system, are illustrated in Fig. 6 . The ␣7-glutamate mechanism proposed by Damaj et al. (1999) is also included, but will not be discussed here.
Disinhibition Model. Freund et al. (1988) , Chiodini et al. (1999) , and Alkondon et al. (2000) speculated that seizures induced by high doses of nicotine are the result of a decrease in GABAergic function. In this model, nicotinic cholinergic fibers provide excitatory input to GABAergic neurons, which in turn inhibit excitatory pyramidal cells. Blockade of the nicotinic cholinergic input to GABAergic neurons (either by desensitization or antagonism) reduces GABAergic input to pyramidal cells, resulting in increased excitability and seizures. Freund et al. (1988) showed that bath application of high concentrations of nicotine induced epileptiform activity in CA1 pyramidal cells in mouse hippocampal slices. This effect was similar to that produced by bath application of bicuculline and was blocked by bath application of GABA or compounds that increase GABAergic function. Chiodini et al. (1999) demonstrated, in rat hippocampal slices, that high doses of nicotine increased hippocampal excitability as measured by the EPSP slope, and presynaptic fiber volley. Application of nicotinic antagonists produced a similar effect. The authors speculated that the increased hippocampal excitability was due to reduced function of nicotinic receptors located on GABAergic interneurons. Alkondon et al. (2000) showed, in human cortical tissue, that nicotinic receptors located on GABAergic neurons modulate the release of GABA onto pyramidal cells as well as other GABAergic neurons. Based on this finding, the authors speculated that reduced activity of nicotinic receptors on GABAergic neurons could result in disinhibition of pyramidal cells and seizures. Evi-dence from Sumikawa's group (Fujii et al., 2000a,b) demonstrated that application of nicotine, as well as nicotinic antagonists, reduced the threshold for long-term potential in hippocampal slices by reducing GABAergic function. Together, these findings indicate that nicotinic effects on brain excitability are mediated primarily through GABAergic systems. Furthermore, these effects seem to be due to a nicotinic receptor-mediated disinhibition of excitatory systems. This conclusion is supported by the current results which detected a robust correlation between nicotinic receptor-mediated seizures and the inhibition of nicotine-stimulated GABA release produced by nicotinic receptor desensitization (Fig. 4C) , and the genetic correlation between nicotine-induced seizures and seizures induced by GABA A receptor antagonists (Fig. 5,  A and B) . Also, a recent report (Wong et al., 2002) demonstrated that pentylenetetrazol-and bicuculline-induced seizure thresholds were decreased in ␣4 null mutant mice, suggesting that nicotinic-cholinergic input drives GABAergic function.
GABA Entrainment
Model. An important function of interneurons is to generate synchronous oscillations in populations of neurons in the central nervous system. In this model, high doses of nicotine produce a widespread synchronous activation (i.e., entrainment) of hippocampal interneurons, which in turn leads to synchronous activity in large populations of hippocampal pyramidal neurons and seizures. Avoli et al. (1996) demonstrated that synchronous GABAmediated potentials underlie the generation of ictal events, which were blocked by the GABA A receptor antagonist bicuculline. A recent report from Köhling et al. (2000) showed that synchronous GABAergic activity facilitated epileptiform activity characterized by high-frequency population spikes (␥ oscillations) that were blocked by bicuculline. The authors concluded that the ␥ oscillations were mediated by synchronous GABA receptor-mediated depolarizations, which may underlie the generation of ictal events. Together, these findings indicate that seizures can also result from increased GABAergic function. The result reported here, and by Damaj et al. (1999) , that MLA can block nicotine-induced seizures and the finding that compounds that block ␣7* receptor function also block maximal electroshock-induced seizures in mice and amygdala kindling-induced seizures in rats (Loscher et al., 2003) are consistent with a mechanism in which seizures can result from synchronous activation of GABAergic systems.
In conclusion, we present evidence that implicates the involvement of ␣4␤2* receptors, as well as ␣7* receptors, in the generation of nicotine-induced seizures. We present two pathways for the generation of nicotine-induced seizures that work primarily through the hippocampal GABAergic system, one involving the activation of ␣7* receptors and one in which ␣4␤2* receptors (and possibly ␣7* receptors) are rendered inactive, either through antagonism or desensitization. Both of these models are consistent with known mechanisms of epileptiform activity. The contribution of direct ␣7* receptormediated effects on glutamatergic function cannot be discounted, but the finding that ␣7*-glutamate interactions may be restricted to early developmental stages raises questions about the role of this system in modulating seizures in adult mice. 
